GoodRx (NASDAQ:GDRX) Given New $8.00 Price Target at Wells Fargo & Company

GoodRx (NASDAQ:GDRX) had its price target lowered by analysts at Wells Fargo & Company from $9.00 to $8.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective indicates a potential upside of 65.12% from the company’s previous close.

GDRX has been the subject of a number of other research reports. Barclays dropped their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Mizuho began coverage on GoodRx in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price target for the company. KeyCorp reduced their price objective on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Morgan Stanley dropped their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Finally, Citigroup cut their target price on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday, January 10th. Five research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.25.

GoodRx Price Performance

Shares of GoodRx stock traded down $0.14 during mid-day trading on Friday, reaching $4.85. 1,006,547 shares of the stock traded hands, compared to its average volume of 1,275,827. The stock has a market capitalization of $1.85 billion, a PE ratio of -161.53, a PEG ratio of 2.46 and a beta of 1.28. The business has a 50-day moving average of $4.70 and a 200 day moving average of $5.76. GoodRx has a fifty-two week low of $4.09 and a fifty-two week high of $9.26. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of GDRX. Point72 Asset Management L.P. purchased a new position in GoodRx during the 3rd quarter valued at about $11,295,000. Clearbridge Investments LLC purchased a new position in shares of GoodRx in the fourth quarter valued at approximately $5,863,000. Rubric Capital Management LP grew its holdings in shares of GoodRx by 25.2% in the third quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock valued at $32,479,000 after purchasing an additional 943,226 shares in the last quarter. Franklin Resources Inc. purchased a new stake in GoodRx during the 3rd quarter worth approximately $5,675,000. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in GoodRx by 303.3% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,061,461 shares of the company’s stock worth $4,936,000 after buying an additional 798,261 shares in the last quarter. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.